Glenmark Pharmaceuticals

Glenmark is a leading global innovative pharmaceutical company committed to enriching lives worldwide. Our vision is to discover possibilities and make lives of patients better across the globe by developing cures for unmet medical needs. We have a rich pipeline of innovative molecules in various phases of development which are targeted in areas of oncology, respiratory and dermatology. Our molecules, in development, include Novel Biologics Entities and Novel Chemical Entities - all of which are first in class globally. In addition to novel monoclonal antibodies, Glenmark has developed its proprietary technology platform 'BEAT' for the production on Bi-Specific Antibodies which will provide next-generation targeted biologics for cancer therapy. (Read more on www.glenmarkpharma.com/BEAT)Our Generics business spans across multiple geographies with the US being our largest market followed by India. Our effort is to make high quality affordable medication accessible to patients across the world. Through our generics medicines we impact over 100 million patients each year globally. We are also a global supplier of high quality API products and a preferred partner for pharmaceutical companies worldwide. Our 13,000 employees globally are dedicated towards our goal of enriching lives globally. Our values - Achievement, Respect and Knowledge bind our workforce together and consistently fuel our growth. At Glenmark, we have created a culture which allows our talent to deliver their best and create positive outcomes for themselves, the organization and the community at large. Through Glenmark Foundation, our CSR activities are largely focussed in the areas of Child Health and over the years we have impacted over 900,000 lives globally. (Read more about Glenmark CSR on www.glenmarkfoundation.com)For more information, log onto www.glenmarkpharma.com.